NEW YORK, NY / ACCESSWIRE / April 28, 2022 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Affirm Holdings, Inc. (NASDAQ:AFRM)
Class Period: February 12, 2021 - February 10, 2022
Lead Plaintiff Deadline: April 29, 2022
The complaint alleges that throughout the class period Affirm Holdings, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Affirm's "buy now, pay-later" service facilitated excessive consumer debt, regulatory arbitrage, and data harvesting; (ii) the foregoing subjected Affirm to a heightened risk of regulatory scrutiny and enforcement action; (iii) Affirm maintained inadequate disclosure controls and procedures and internal control over financial reporting; (iv) accordingly, Affirm's tweet for its second quarter 2022 financial results contained selected metrics that made it appear that the Company had performed better than it actually did; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in AFRM: https://www.kleinstocklaw.com/pslra-1/affirm-holdings-inc-loss-submission-form?id=26498&from=1
Akebia Therapeutics, Inc. (NASDAQ:AKBA)
Class Period: June 28, 2018 - September 2, 2020
Lead Plaintiff Deadline: May 13, 2022
According to the complaint, Akebia Therapeutics, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's lead investigational product candidate, vadadustat, was not as safe in treating non-dialysis dependent chronic kidney disease patients with anemia as defendants had represented; (ii) as a result, defendants overstated the clinical prospects of a Phase 3 clinical program for vadadustat; (iii) accordingly, defendants also overstated vadadustat's overall commercial and regulatory prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in AKBA: https://www.kleinstocklaw.com/pslra-1/akebia-therapeutics-inc-loss-submission-form?id=26498&from=1
Lucid Group, Inc. (NASDAQ:LCID)
This lawsuit is on behalf of a class of all persons and entities who purchased or otherwise acquired Lucid common stock between November 15, 2021, and February 28, 2022, inclusive.
Lead Plaintiff Deadline: May 31, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and failed to disclose material adverse facts about Lucid's business and operations. Specifically, the Company overstated its production capabilities while concealing that "extraordinary supply chain and logistics challenges" were hampering Lucid's operations. As a result of the defendants' wrongful acts and omissions, and the significant decline in the market value of Lucid's common stock, Lucid investors have suffered significant damages.
Learn about your recoverable losses in LCID: https://www.kleinstocklaw.com/pslra-1/lucid-group-inc-loss-submission-form?id=26498&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: The Klein Law Firm
View source version on accesswire.com: